Verici Dx (LON:VRCI) Shares Down 5.4%

Verici Dx plc (LON:VRCIGet Free Report)’s stock price fell 5.4% during mid-day trading on Monday . The stock traded as low as GBX 8.50 ($0.11) and last traded at GBX 8.75 ($0.11). 426,591 shares traded hands during mid-day trading, an increase of 39% from the average session volume of 306,138 shares. The stock had previously closed at GBX 9.25 ($0.12).

Verici Dx Trading Down 5.4 %

The stock has a market capitalization of £14.90 million, a P/E ratio of -175.00 and a beta of 1.51. The company has a current ratio of 2.58, a quick ratio of 8.49 and a debt-to-equity ratio of 9.28. The company has a 50-day moving average price of GBX 9.40 and a 200 day moving average price of GBX 8.85.

Verici Dx Company Profile

(Get Free Report)

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.

See Also

Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.